Bristol Myers Squibb’s Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains
Bristol Myers Squibb has expanded Opdivo’s first-in-class win in pre-surgery non-small cell lung cancer, teeing up a potential FDA filing.
Opdivo added to chemothera...